title: Possible problem with Optipen Pro-1: should diabetic patients continue to use this product?
authors.forename: Damla
authors.initials: D
authors.lastname: Goksen
authors.forename: Sukran
authors.initials: S
authors.lastname: Darcan
authors.forename: Muammer
authors.initials: M
authors.lastname: Buyukinan
authors.forename: Emine
authors.initials: E
authors.lastname: Kurt
mesh_terms: D000293:Adolescent; D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004868:Equipment Failure; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007279:Injections, Subcutaneous / Q000295:instrumentation*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine